Catalent Opens Cell Therapy Facility in Belgium
The US-headquartered CDMO said the 5,600 m2 cell therapy manufacturing space houses multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing through to late-stage clinical and commercial-scale supply.
The facility has been designed to be both EMEA and FDA compliant, with Grade B and C suites to support high-throughput processes and accommodate bioreactor-scale cell therapy manufacturing as well as on-site quality control (QC) laboratories and warehousing.
Catalent’s Gosselies campus already includes a 6,200 m2 clinical manufacturing facility offering customers advanced clinical and commercial supply solutions. Altogether, the Belgian site provides process and analytical development labs, more than 20 CGMP grade B and C cleanrooms, dedicated QC labs, qualified person (QP) services and warehousing.
Gosselies also offers separate plasmid DNA (pDNA) development and large-scale manufacturing facilities, R&D, process development, QC lab and multiple CGMP production suites.
Manja Boerman, president, BioModalities (Cell, Gene and Protein Therapies), said the CDMO’s platform enables fully integrated cell therapy services at multiple locations.
Author: Dede Williams, Freelance Journalist
